Fibrodysplasia Ossificans Progressiva Fop Market Size

DelveInsight's 'Fibrodysplasia Ossificans Progressiva (FOP)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Fibrodysplasia Ossificans Progressiva (FOP) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Fibrodysplasia Ossificans Progressiva (FOP) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028

Fibrodysplasia ossificans progressiva (FOP) - Disease Understanding and Treatment Algorithm

According to the National Institute of Health (NIH), Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders and proceeding down the body and into the limbs. Extra-skeletal bone formation causes a progressive loss of mobility as the joints become affected. Inability to fully open the mouth may cause difficulty in speaking and eating. Over time, people with this disorder may experience malnutrition due to their eating problems. They may also have breathing difficulties as a result of extra bone formation around the rib cage that restricts expansion of the lungs. Its prevalence is nearly one per 2 million population worldwide.

The DelveInsight Fibrodysplasia Ossificans Progressiva market report gives the thorough understanding of the Fibrodysplasia Ossificans Progressiva by including details such as disease introduction, causes, pathophysiology, signs and symptoms, developmental and clinical aspects of Fibrodysplasia Ossificans Progressiva, genetics of FOP, pathophysiology, clinical manifestations in FOP and diagnosis. It also provides treatment algorithms and treatment guidelines for Fibrodysplasia Ossificans Progressiva in the US, Europe, and Japan.


Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology

The Fibrodysplasia Ossificans Progressiva epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Fibrodysplasia Ossificans Progressiva, Total Diagnosed Prevalent Cases of Fibrodysplasia Ossificans Progressiva, Gender-Specific Diagnosed Prevalence Cases of Fibrodysplasia Ossificans Progressiva, Age-specific Diagnosed Prevalence Cases of Fibrodysplasia Ossificans Progressiva) scenario of Fibrodysplasia Ossificans Progressiva in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

As per the study conducted by P. Antonio et al., titled “Osteochondral Diseases and Fibrodysplasia Ossificans Progressiva” the most severe and disabling disorder of extra skeletal ossification i.e. FOP in humans has a worldwide prevalence of approximately, one in two million of individuals. Paternal age effect is one of the most important factors leading to this genetic disorder. Diagnosis of FOP leads to many errors which results in detrimental long-term effects. Most patients are misdiagnosed before the appearance of heterotopic ossification and undergo unnecessary diagnostic and therapeutic procedures that alter the natural history of the disease, causing permanent harm. Clinical and radiographic features are important parameters for the correct diagnosis of FOP.

A study conducted by K. Frederick et al. titled, “Fibrodysplasia ossificans progressiva” stated that FOP is extremely rare with a worldwide prevalence of approximately one in two million. Most cases arise as a result of a spontaneous new mutation. When observed, the genetic transmission is autosomal dominant and can be inherited from either mothers or fathers.


Fibrodysplasia Ossificans Progressiva (FOP) Drug Chapters

This segment of the Fibrodysplasia Ossificans Progressiva report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Fibrodysplasia Ossificans Progressiva, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Fibrodysplasia Ossificans Progressiva and awareness of the disease. The overall dynamics of Fibrodysplasia Ossificans Progressiva market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Ipsen, Regeneron Pharmaceuticals, Blueprint Medicines, and some others, will significantly increase the market during the forecast period (2019-2028).   


Fibrodysplasia Ossificans Progressiva (FOP) Market Outlook

The Fibrodysplasia Ossificans Progressiva market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Currently, there are no effective medical treatment options to prevent the formation of heterotopic bone in FOP. Removal of heterotopic bone is avoided because surgical trauma to tissues is likely to induce additional bone formation. The treatment pattern follows Class I, Class II and Class III medications regimen. Class I includes use of Corticosteroids (Prednisone), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 inhibitors. Class II includes Leukotriene inhibitors (Montelukast), Mast Cell Stabilizers (Cromolyn), Aminobisphosphonates (Pamidronate; Zoledronate), and Specific Tyrosine Kinase Inhibitors (Imatinib). Prednisone is one of the majorly used drug to get symptomatic relief from FOP. It possesses anti-inflammatory action which includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of the inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. Glucocorticoids are used to manage symptoms of flare-ups affecting major joints of the appendicular skeleton, especially when used immediately after the onset of a flare-up. Non-steroidal anti-inflammatory agents, cyclooxygenase-2 inhibitors, mast cell stabilizers, and leukotriene inhibitors are reported by patients to manage chronic pain and ongoing disease progression.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Fibrodysplasia Ossificans Progressiva in 7MM is expected to change from 2019-2028.


Fibrodysplasia Ossificans Progressiva (FOP) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Fibrodysplasia Ossificans Progressiva (FOP) such as Palovarotene (Ipsen), Garetosmab (REGN2477) (Regeneron Pharmaceuticals), BLU-782 (Blueprint Medicines), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Fibrodysplasia Ossificans Progressiva (FOP) market.


Fibrodysplasia Ossificans Progressiva (FOP) Report Insights

• Patient Population

• Therapeutic Approaches

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Fibrodysplasia Ossificans Progressiva (FOP) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Fibrodysplasia Ossificans Progressiva (FOP) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Fibrodysplasia Ossificans Progressiva (FOP)market

• Organize sales and marketing efforts by identifying the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP)market

• To understand the future market competition in the Fibrodysplasia Ossificans Progressiva (FOP) market.

1. Key Insights

2. Fibrodysplasia Ossificans Progressiva (FOP) Market Overview at a Glance

2.1. Market Share (%) Distribution of Fibrodysplasia Ossificans Progressiva (FOP) in 2017

2.2. Market Share (%) Distribution of Fibrodysplasia Ossificans Progressiva (FOP) in 2028

3. Disease Background and Overview: Fibrodysplasia Ossificans Progressiva (FOP) (SMA)

3.1. Introduction

3.2. Causes

3.3. Signs and Symptoms

3.4. Pathophysiology

3.5. Developmental and Clinical Aspects of Fibrodysplasia Ossificans Progressiva (FOP)

3.6. Genetics

3.7. Pathophysiology

3.8. Differential Diagnosis

3.9. Diagnostic Algorithm

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Patient Population of Fibrodysplasia Ossificans Progressiva

4.3. 7MM Total Diagnosed Patient Population of Fibrodysplasia Ossificans Progressiva

5. Country Wise-Epidemiology of Fibrodysplasia Ossificans Progressiva

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in the United States

5.1.3. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in the United States

5.1.4. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in the United States

5.1.5. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in the United States

5.2. EU5 Countries

5.2.1. Assumptions and Rationale

5.3. Germany

5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Germany

5.3.2. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Germany

5.3.3. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in Germany

5.3.4. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in Germany

5.4. France

5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in France

5.4.2. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in France

5.4.3. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in France

5.4.4. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in France

5.5. Italy

5.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Italy

5.5.2. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Italy

5.5.3. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in Italy

5.5.4. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in Italy

5.6. Spain

5.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Spain

5.6.2. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Spain

5.6.3. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in Spain

5.6.4. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in Spain

5.7. United Kingdom

5.7.1. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in the United Kingdom

5.7.2. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in the United Kingdom

5.7.3. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in the United Kingdom

5.7.4. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in the United Kingdom

5.8. Japan

5.8.1. Assumptions and Rationale

5.8.2. Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Japan

5.8.3. Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Japan

5.8.4. Fibrodysplasia Ossificans Progressiva (FOP) Type specific Diagnosed Prevalence in Japan

5.8.5. Fibrodysplasia Ossificans Progressiva (FOP) Mutation specific Prevalence in Japan

6. Treatment

6.1. Treatment strategies for FOP

6.2. Pathologic and Pathophysiologic-based treatment of FOP

6.2.1. Corticosteroids

6.2.2. Cyclo-Oxygenase-2 (COX-2) Inhibitors

6.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

6.2.4. Mast Cell Inhibitors

6.2.5. Bisphosphonates

6.2.6. Imatinib (specific tyrosine kinase inhibitor)

6.2.7. Muscle Relaxants

6.3. Special Medical Considerations in FOP

6.4. Acute & Chronic Pain Management in FOP

6.5. Treatment Guidelines, the International FOP Association (IFOPA)

6.5.1. General Recommendations

6.5.2. General Recommendations for Medications

6.5.3. Definitive Therapeutic Targets in FOP

7. Treatment Guidelines, the International FOP Association (IFOPA)

8. Unmet Needs

9. Emerging Drugs

9.1. Key Cross Competition

9.2. Palovarotene: Ipsen

9.2.1. Product Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Product Profile

9.3. Garetosmab (REGN2477): Regeneron Pharmaceuticals

9.3.1. Product Description

9.3.2. Other Developmental Activities

9.3.3. Clinical Development

9.3.4. Product Profile

9.4. BLU-782: Blueprint Medicines

9.4.1. Product Description

9.4.2. Other Development Activities

9.4.3. Clinical Development

9.4.4. Product Profile

10. Fibrodysplasia Ossificans Progressiva: 7 Major Market Analysis

10.1. Key Findings

10.2. Market Size of Fibrodysplasia Ossificans Progressiva (FOP) in 7MM

11. The United States Market Outlook

11.1. United States Market Size

11.1.1. Total Market size of Fibrodysplasia Ossificans Progressiva

11.1.2. Market Size by Therapies

12. EU-5 Countries: Market Outlook

12.1. Germany

12.1.1. Total Market size of Fibrodysplasia Ossificans Progressiva

12.1.2. Market Size by Therapies

12.2. France

12.2.1. Total Market Size of Fibrodysplasia Ossificans Progressiva

12.2.2. Market Size by Therapies

12.3. Italy

12.3.1. Total Market Size of Fibrodysplasia Ossificans Progressiva

12.3.2. Market Size by Therapies

12.4. Spain

12.4.1. Total Market Size of Fibrodysplasia Ossificans Progressiva

12.4.2. Market Size by Therapies

12.5. United Kingdom

12.5.1. Total Market Size of Fibrodysplasia Ossificans Progressiva

12.5.2. Market Size by Therapies

13. Japan: Market Outlook

13.1. Japan market Size

13.1.1. Total Market Size of Fibrodysplasia Ossificans Progressiva

13.1.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Table 1: Class I Medications

Table 2: Class II Medications

Table 3: Total Diagnosed Population of Fibrodysplasia Ossificans Progressiva (FOP) in the 7MM (2017-2028)

Table 4: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in the United States (2017-2028)

Table 5: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in the United States (2017-2028)

Table 6: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in the United States (2017-2028)

Table 7: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in the United States (2017-2028)

Table 8: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Germany (2017-2028)

Table 9: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Germany (2017-2028)

Table 10: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in Germany (2017-2028)

Table 11: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in Germany (2017-2028)

Table 12: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in France (2017-2028)

Table 13: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in France (2017-2028)

Table 14: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in France (2017-2028)

Table 15: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in France (2017-2028)

Table 16: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Italy (2017-2028)

Table 17: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Italy (2017-2028)

Table 18: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in Italy (2017-2028)

Table 19: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in Italy (2017-2028)

Table 20: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Spain (2017-2028)

Table 21: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Spain (2017-2028)

Table 18: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in Spain (2017-2028)

Table 23: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in Spain (2017-2028)

Table 24: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in the United Kingdom (2017-2028)

Table 25: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Table 26: Fibrodysplasia Ossificans Progressiva (FOP) Gender-Specific Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Table 27: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Table 28: Fibrodysplasia Ossificans Progressiva (FOP) Prevalent Cases in Japan (2017-2028)

Table 29: Fibrodysplasia Ossificans Progressiva (FOP) Diagnosed Prevalent Cases in Japan (2017-2028)

Table 30: Fibrodysplasia Ossificans Progressiva (FOP) Gender specific Diagnosed Prevalent Cases in Japan (2017-2028)

Table 31: Fibrodysplasia Ossificans Progressiva (FOP) Age specific Diagnosed Prevalent Cases in Japan (2017-2028)

Table 32: Comparison of emerging drugs under development

Table 33: Clinical Trial Description

Table 34: Clinical Trial Description

Table 35: Clinical Trial Description

Table 36: United States Market Size of Fibrodysplasia Ossificans Progressiva, USD Million (2017-2028)

Table 37: Market size of Fibrodysplasia Ossificans Progressiva by therapies in United States, in USD Million (2017-2028)

Table 38: Market Size of Fibrodysplasia Ossificans Progressiva in Germany, in USD Million (2017-2028)

Table 39: Market size of Fibrodysplasia Ossificans Progressiva by therapies in Germany, in USD Million (2017-2028)

Table 40: Market Size of Fibrodysplasia Ossificans Progressiva in France, in USD Million (2017-2028)

Table 41: Market size of Fibrodysplasia Ossificans Progressiva by therapies in France, in USD Million (2017-2028)

Table 42: Market Size of Fibrodysplasia Ossificans Progressiva in Italy, in USD Million (2017-2028)

Table 43: Market size of Fibrodysplasia Ossificans Progressiva by therapies in Italy, in USD Million (2017-2028)

Table 44: Market Size of Fibrodysplasia Ossificans Progressiva in Spain, in USD Million (2017-2028)

Table 45: Market size of Fibrodysplasia Ossificans Progressiva by therapies in Spain, in USD Million (2017-2028)

Table 46: Market Size of Fibrodysplasia Ossificans Progressiva in the UK, in USD Million (2017-2028)

Table 47: Market size of Fibrodysplasia Ossificans Progressiva by therapies in the UK, in USD Million (2017-2028)

Table 48: Market Size of Fibrodysplasia Ossificans Progressiva in Japan, in USD Million (2017-2028)

Table 49: Market size of Fibrodysplasia Ossificans Progressiva by therapies in Japan, in USD Million (2017-2028)

Figure 1: Signs and Symptoms of FOP

Figure 2: Clinical features of fibrodysplasia ossificans progressiva (FOP)

Figure 3: Schematic illustration of the ACVR1 protein and all mutations

Figure 4: Molecular mechanism of BMP-ACVR1 signaling and Fibrodysplasia Ossificans Progressiva

Figure 5: Heterotopic ossification in FOP

Figure 6: Clinical features of fibrodysplasia ossificans progressiva (FOP)

Figure 7: Symptomatic Treatment Schema In Fibrodysplasia Ossificans Progressiva (FOP)

Figure 8: Targets & Potential Treatments for FOP

Figure 9: Algorithmic approach to acute joint pain or periarticular pain in FOP

Figure 10: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Patient Population in the 7MM (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in the United States (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in the United States (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in the United States (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in the United States (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in Germany (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in Germany (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in Germany (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in Germany (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in France (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in France (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in France (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in France (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in Italy (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in Italy (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in Italy (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in Italy (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in Spain (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in Spain (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in Spain (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in Spain (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in the United Kingdom (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in the United Kingdom (2017-2028)

Figure 11: Fibrodysplasia Ossificans Progressiva (FOP) Total Prevalent Cases in Japan (2017-2028)

Figure 12: Fibrodysplasia Ossificans Progressiva (FOP) Total Diagnosed Prevalent Cases in Japan (2017-2028)

Figure 13: Fibrodysplasia Ossificans Progressiva (FOP) Total Gender-Specific Diagnosed Prevalent Cases in Japan (2017-2028)

Figure 14: Fibrodysplasia Ossificans Progressiva (FOP) Age-specific Diagnosed Prevalent Cases in Japan (2017-2028)

Figure 39: Unmet Needs of Fibrodysplasia Ossificans Progressiva

Figure 40: Market Size of Fibrodysplasia Ossificans Progressiva in the United States, USD Millions (2017-2028)

Figure 41: Market size of Fibrodysplasia Ossificans Progressiva by therapies in the US, in USD Million (2017-2028)

Figure 42: Market Size of Fibrodysplasia Ossificans Progressiva in Germany, USD Million (2017-2028)

Figure 43: Market Size of Fibrodysplasia Ossificans Progressiva by therapies, in Germany, in USD Million (2017-2028)

Figure 44: Market Size of Fibrodysplasia Ossificans Progressiva in France, USD Million (2017-2028)

Figure 45: Market Size of Fibrodysplasia Ossificans Progressiva by therapies, in France, in USD Million (2017-2028)

Figure 46: Market Size of Fibrodysplasia Ossificans Progressiva in Italy, USD Million (2017-2028)

Figure 47: Market Size of Fibrodysplasia Ossificans Progressiva by therapies in Italy, in USD Million (2017-2028)

Figure 48: Market Size of Fibrodysplasia Ossificans Progressiva in Spain, USD Million (2017-2028)

Figure 49: Market Size of Fibrodysplasia Ossificans Progressiva by therapies in Spain, in USD Million (2017-2028)

Figure 50: Market Size of Fibrodysplasia Ossificans Progressiva in the UK, USD Million (2017-2028)

Figure 51: Market Size of Fibrodysplasia Ossificans Progressiva by therapies in the UK, in USD Million (2017-2028)

Figure 52: Market Size of Fibrodysplasia Ossificans Progressiva in Japan, USD Million (2017-2028)

Figure 53: Market Size of Fibrodysplasia Ossificans Progressiva by therapies in Japan, in USD Million (2017-2028)

Figure 54: Market Drivers

Figure 55: Market Barriers

  • Tags:
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progressi...
  • Fibrodysplasia Ossificans Progress...

Forward to Friend

Need A Quote